Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

Autor: A. Sarah Walker, Osamah Hamouda, Virginie Rondeau, Maria Dorrucci, Heiner C. Bucher, Maria Prins, Geneviève Chêne, Kholoud Porter, Caroline A. Sabin, Rodolphe Thiébaut, Benoît Marin, Dominique Costagliola
Přispěvatelé: Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Neuroépidémiologie Tropicale et Comparée (NETEC), Université de Limoges (UNILIM)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Basel Institute for Clinical Epidemiology, University Hospital Basel [Basel], Epidémiologie Clinique et Traitement de l'Infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Dipartimento di Malattie Infettive, Reparto di Epidemiologia, Istituto Superiore di Sanita [Rome], Department of Infectious Disease Epidemiology, Robert Koch Institute [Berlin] (RKI), Cluster Infectious Diseases, Amsterdam BioMed Cluster, Medical Research Council Clinical Trials Unit (MRC CTU), University College of London [London] (UCL), Research Department of Infection and Population Health [London], CASCADE has been funded through grants from the European Union BMH4-CT97-2550, QLK2-2000-01431, QLRT-2001-01708 and LSHP-CT-2006-018949., Istituto Superiore di Sanità (ISS), AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Infectious diseases
Jazyk: angličtina
Rok vydání: 2009
Předmět:
Male
MESH: CD4 Lymphocyte Count
medicine.medical_treatment
CD4 cell count
Disease
MESH: Epidemiologic Methods
MESH: Antiretroviral Therapy
Highly Active

Hepatitis
Liver disease
0302 clinical medicine
Antiretroviral Therapy
Highly Active

Neoplasms
Immunology and Allergy
MESH: Neoplasms
030212 general & internal medicine
Causes of death
Immunodeficiency
MESH: Aged
0303 health sciences
MESH: Middle Aged
MESH: AIDS-Related Opportunistic Infections
Liver Diseases
Immunosuppression
Middle Aged
Human Immunodeficiency Virus/AIDS
Antiretroviral therapy
3. Good health
Infectious Diseases
Cardiovascular Diseases
MESH: Young Adult
Female
Viral disease
Adult
medicine.medical_specialty
MESH: Immune Tolerance
MESH: Liver Diseases
Adolescent
Immunology
Article
Young Adult
03 medical and health sciences
Acquired immunodeficiency syndrome (AIDS)
Internal medicine
Immune Tolerance
medicine
Humans
Seroconversion
highly active
Aged
MESH: Acquired Immunodeficiency Syndrome
MESH: Adolescent
Acquired Immunodeficiency Syndrome
MESH: Humans
AIDS-Related Opportunistic Infections
030306 microbiology
business.industry
MESH: Cardiovascular Diseases
MESH: Adult
medicine.disease
MESH: Male
CD4 Lymphocyte Count
Neoplasm
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Bacterial infection
Epidemiologic Methods
business
MESH: Female
Zdroj: AIDS
AIDS, Lippincott, Williams & Wilkins, 2009, 23 (13), pp.1743-53. ⟨10.1097/QAD.0b013e32832e9b78⟩
AIDS. Official journal of the international AIDS Society
AIDS. Official journal of the international AIDS Society, 2009, 23 (13), pp.1743-53. ⟨10.1097/QAD.0b013e32832e9b78⟩
AIDS (London, England), 23(13), 1743-1753. Lippincott Williams and Wilkins
ISSN: 0269-9370
1473-5571
Popis: International audience; OBJECTIVE: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART). DESIGN: Observational multicentre cohorts. METHODS: Twenty-three cohorts of adults with estimated dates of human immunodeficiency virus (HIV) seroconversion were considered. Patients were seroconverters followed within the cART era. Measurements were latest CD4, nadir CD4 and time spent with CD4 cell count less than 350 cells/microl. Outcomes were specific causes of death using a standardized classification. RESULTS: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths. For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%). Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression. No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA. CONCLUSION: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication. Avoiding profound and mild immunodeficiency, through earlier initiation of cART, may impact on morbidity and mortality of HIV-infected patients.
Databáze: OpenAIRE